1. Use of fulvestrant in the preparation of a pharmaceutical formulation
for the treatment of a benign or malignant disease of the breast or reproductive tract by intra-muscular administration, wherein the formulation comprises fulvestrant in a ricinoleate vehicle, a pharmaceutically
acceptable non-aqueous ester solvent, and a pharmaceutically acceptable alcohol, and wherein the formulation is adapted for attaining
Seite 13
O2015_012

a therapeutically significant blood plasma fulvestrant concentration for
at least 2 weeks.